Cerus Corporation
$ 1.92
1.59%
13 Apr - close price
- Market Cap 363,205,000 USD
- Current Price $ 1.92
- High / Low $ 1.97 / 1.87
- Stock P/E N/A
- Book Value 0.33
- EPS -0.08
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.26 %
- 52 Week High 2.96
- 52 Week Low 1.15
About
Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-07-30 | 2025-04-30 | 2025-03-03 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 | 2023-08-02 | 2023-05-04 |
| Reported EPS | -0.01 | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 | -0.06 | -0.09 |
| Estimated EPS | -0.0075 | -0.03 | -0.0225 | -0.05 | -0.01 | -0.03 | -0.04 | -0.05 | -0.02 | -0.05 | -0.06 | -0.07 |
| Surprise | -0.0025 | 0.0299 | -0.0075 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0.01 | 0.02 | 0 | -0.02 |
| Surprise Percentage | -33.3333% | 99.6667% | -33.3333% | 20% | 0% | 33.3333% | 25% | 0% | 50% | 40% | 0% | -28.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2026-04-03 22:09:16
Cerus Corp.'s Chief Legal Officer, Chrystal Jensen, was granted 200,000 Restricted Stock Units (RSUs) as a stock-based compensation award on April 1, 2026. These RSUs, valued at $0.00 per share for compensation purposes, will vest in full one year from the grant date, provided Jensen remains in continuous service. Following this grant, Jensen directly holds 1,146,131 shares of Cerus common stock, reinforcing her equity stake in the company.
2026-04-03 22:09:16
Cerus Corporation's Chief Financial Officer, Kevin Dennis Green, has received a grant of 200,000 Restricted Stock Units (RSUs) of common stock. This grant, valued at $0.00 per share as a compensation award, will vest fully one year from the grant date, subject to his continuous service to the company. Following this transaction, Green's direct holdings in Cerus common shares have increased to 1,240,551.
2026-04-02 02:40:46
This page on Stock Titan provides comprehensive access to SEC filings for Cerus Corporation (NASDAQ: CERS), including 10-K, 10-Q, and 8-K forms. It offers detailed financial information, business risks, and corporate governance updates, enhanced with AI-powered summaries and impact analysis for investors. Recent filings include an amended 13G/A from Baker Brothers disclosing Cerus shares and an 8-K detailing a leadership transition where the CEO assumed the chair role.
2026-04-01 20:40:46
This article provides a technical analysis and stock price forecast for Cerus Corp (CERS) from Intellectia.AI. It indicates a "Strong Buy" consensus based on various technical signals, including moving averages and oscillators. The analysis details key momentum indicators, support and resistance levels, and Cerus Corp's performance relative to its moving averages.
2026-03-31 08:40:00
This article provides the current stock price quote and chart for Cerus Corp (CERS). It is hosted on Capital.com, an online trading platform.
2026-03-26 21:09:21
Vanguard has filed an amended Schedule 13G/A, reporting a 0% beneficial ownership in Cerus Corp (NASDAQ: CERS) following an internal realignment that took effect on January 12, 2026. This realignment means that certain Vanguard subsidiaries will now report their holdings separately. The filing indicates that Vanguard itself no longer holds voting or dispositive power over Cerus Corp shares.
